Product Pipeline Summary
NM127 is a fast acting nanoenabled pain therapeutic, which is based on an endogenous peptide delta opioid receptor-selective agonist. NM127 is indicated for the treatment of moderate to severe pain. Non-parenteral NM127 is comparable to subcutaneous morphine in preclinical pain models and the product has an attractive side effect profile, which differentiates it from the current marketed mu opioid receptor agonists. NM127 is being developed for the treatment of neuropathic pain, a condition that is poorly served by current products.
Nanomerics' MET enables the formulation of therapeutic levels of high LogP drugs in an optically transparent liquid. Nanomerics MET formulations do not show ocular irritation in preclinical models (Biomacromolecules, 2006, 7: 3452). Nanomerics' MET is a solution for the topical ocular delivery of hydrophobic drugs, without the use of irritating surfactants and oils. NM133 is a cyclosporine A formulation indicated for relevant ocular conditions.
Nanomerics' nano-enabled orally active form of Amphotericin B is equipotent to the parentally administered liposomal form with kidney sparing biodistribution minimizing kidney toxicity.
Amphotericin B is a very important anti-fungal drug but also has activity against Leishmaniasus thus potentially making this drug easily accessible to millions of people at risk from Leishmaniasis.